CUTANEOUS LEISHMANIASIS

CLINICAL RESPONSE OF INTRALESIONAL MEGLUMINE ANTIMONIATE IN THE TREATMENT

Abstract

Objective: The aim of study was to evaluate clinical response of
Intralesional Meglumine Antimoniate (MA) in the treatment of Cutaneous Leishmaniasis (CL). Design: A case control
interventional prospective study Place & duration of study: Scouts Hospital Wana, from Feb 2003 to Dec 2004.
Materials & Methods: A total number of sixty patients were included in the study on the basis of demonstration of LT
bodies in the slit skin smears and skin biopsies. These patients were randomly distributed in three groups. Group 1
constituted 20 patients who received 0.5 ml (42.5 mg of MA) in each lesion six days a week for a total number of 15
injections. Group II included 20 patients who received o.5 ml (42.5 mg of MA) in each lesion on alternate days for a
total number of 15 injections. Group III included 20 patients, who were unwilling for treatment due to personal reasons
and were used as a control group. Patients were then observed on 30 days and followed up at 3 and 6 months.
Results: In group I over all cure rate was found to be, 12 of 20 (60% patients. In group II 17 of 20 (85%) patients and
in group III spontaneous healing was found in 3 of 20 (15%) patients. Conclusions: Intralesional administration of
pentavalent Antimonial compound (Meglumine Antimoniate) is an effective method of treatment in cutaneous
Leishmaniasis.